scholarly journals Streptococcal pharyngitis in children with painful throat: missed opportunities for rheumatic heart disease prevention in endemic area of Africa

2017 ◽  
Vol 7 (4) ◽  
pp. 421-423
Author(s):  
Geoffrey Madeira ◽  
Daniel Chicavel ◽  
Alcides Munguambe ◽  
José Langa ◽  
Ana Mocumbi
Global Heart ◽  
2018 ◽  
Vol 13 (4) ◽  
pp. 477
Author(s):  
L. Allen ◽  
K.C. Cook ◽  
B.L. Spencer ◽  
M. Allen ◽  
N. Gidlow ◽  
...  

Global Heart ◽  
2014 ◽  
Vol 9 (1) ◽  
pp. e331-e332
Author(s):  
Samantha Colquhoun ◽  
Titus Nasi ◽  
Teatro Tira ◽  
Gano Mwareow ◽  
Maliesi Latasi ◽  
...  

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S18-S19
Author(s):  
James Ray Mata Lim ◽  
Bobby L Boyanton ◽  
Julie George ◽  
Matthew Sims

Abstract Background Treatment of Group A Streptococcus (GAS) pharyngitis is imperative to mitigate sequelae such as rheumatic heart disease. The need for treatment of Group C Streptococcus (GCS) and Group G Streptococcus (GGS) pharyngitis is unclear, as rheumatogenic sequelae have not been well documented. Our institution switched from culture to molecular confirmation testing for a negative rapid streptococcal antigen detection test. Cultures reported GAS whereas molecular testing reported GAS, GCS, and GGS. We performed a retrospective chart review to examine the epidemiological differences of GAS, GCS, and GGS pharyngitis. Methods Records were obtained of pharyngeal samples from patients sent for testing at Beaumont Health Laboratory. In all, 92,369 records were analyzed. There were 47,106 records of cultures from May 2012 through December 2014 and 45,263 records of molecular testing from May 2015 to December 2017. Samples positive for either GCS or GGS were reported as positive for Group CG Streptococcus (GCGS). Epidemiological factors were evaluated. If available, electronic records from GCGS positive samples were evaluated for clinical features, antibiotics used, and sequelae or complications reported. Results Molecular testing showed GAS positivity of 9.3% (n = 4,189) and GCGS positivity of 1.5% (n = 687). GCGS pharyngitis was more likely during the summer months and in young adults 13 years and older than children under 13 years. GAS pharyngitis was more likely during spring months and in children aged 4–9 years. Mean age of GCGS pharyngitis was 13 vs. 8.6 years for GAS pharyngitis. Similar results were obtained for GAS between culture and molecular testing records. Amoxicillin was most often prescribed for treatment of GCGS. There were few instances of severe GCGS exudative or recurrent pharyngitis that required hospitalization or tonsillectomy. There were no cases of rheumatic fever or rheumatic heart disease associated with GCGS. Conclusion This is the largest study based on our literature review to evaluate the epidemiology of GAS, GCS, and GGS pharyngitis in children and adults. We found a seasonal and age difference between GAS and GCGS. Complications were rare, and no rheumatogenic sequelae were noted from GCGS infections. Disclosures All Authors: No reported Disclosures.


Sign in / Sign up

Export Citation Format

Share Document